The Latest Cardiac and Vascular News
DUBLIN, Sept. 22, 2020 /PRNewswire/ — Medtronic plc (NYSE:MDT), the global leader in medical technology, has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA) for the TYRX™ Absorbable Antibacterial Driveline Wrap, which is intended to securely hold a percutaneous driveline in patients receiving a ventricular assist device (VAD). […]
SALINAS, Calif., Sept. 23, 2020 /PRNewswire/ — During unprecedented challenges in healthcare, Salinas Valley Memorial Healthcare System (SVMHS) is providing medical leadership during COVID-19 and earning awards for exceptional patient care in the area of heart treatment. SVMHS is one of only 60 hospitals nationwide to receive the American College of Cardiology’s NCDR […]
Company Advances Second Cardiac Myosin Inhibitor SOUTH SAN FRANCISCO, Calif., Sept. 23, 2020 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first participants have been dosed in a Phase 1 placebo-controlled, single ascending dose clinical study of CK-3772271 (CK-271). CK-271 is a second cardiac myosin inhibitor, discovered […]
TEL AVIV, Israel, Sept. 22, 2020 /PRNewswire/ — MedHub, a med-tech company that is leveraging AI to help interventional cardiologists make better decisions, announced today that its AutoCathFFR system has been certified to bear the CE Mark, signifying compliance with the European Union’s health and environmental safety regulations. “Following our recent AMAR regulatory approval, the […]
– CE Mark for MitraClip G4 offers physicians an innovative next-generation system with more options for mitral valve repair using proven clip-based technology – MitraClip is a first-of-its-kind transcatheter mitral valve therapy, now on its fourth generation, improving further on MitraClip’s history as a safe and effective treatment option ABBOTT […]
WESTMINSTER, Colo., Sept. 21, 2020 (GLOBE NEWSWIRE) — ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) under the Coronavirus Treatment Acceleration Program (CTAP) to evaluate AB201 […]
Study published in Mayo Clinic Proceedings supports multiple cardiovascular risk reductions SALT LAKE CITY, Sept. 17, 2020 /PRNewswire/ — A new study, the most comprehensive analysis of the role of omega-3 dosage on cardiovascular prevention to date, provides compelling evidence for consuming more EPA and DHA (eicosapentaenoic acid and docosahexaenoic acid, respectively) […]
Study will evaluate the impact of remote patient monitoring on clinical outcomes, readmission rates, and patient satisfaction following a transcatheter aortic valve replacement procedure SAN JOSE, Calif.–(BUSINESS WIRE)–VitalConnect®, Inc., a leader in remote and in-hospital wearable biosensor technology, announced today that it has begun the TELESTAR-TAVR clinical study (Deployment of Telemedicine […]
CAMBRIDGE, Mass. & PARMA, Italy–(BUSINESS WIRE)–Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients and Chiesi Farmaceutici S.p.A., an international research-focused healthcare group (Chiesi Group), today announced a collaboration aimed at the discovery and development […]
Corventive Now Delivers Evidence-Based Content to Enhance Patient Care. NEWTOWN, Pa., Sept. 15, 2020 /PRNewswire/ — Corventive Health, a provider of cloud-based and AI technology solutions, announced its plan to integrate American College of Cardiology (“ACC”) evidence-based content into its innovative cardiac solutions. Incorporating ACC clinical content enables Corventive to deliver insights designed […]
